8-K: ARTELO Faces Nasdaq Delisting Threat Over Annual Meeting

Artelo Biosciences received a Nasdaq notice of non-compliance for failing to hold its annual meeting, adding to existing delisting concerns over minimum stockholders' equity.

Summary

• Artelo Biosciences, Inc. (ARTL) received a notice from Nasdaq on January 14, 2026, indicating non-compliance with Listing Rule 5620(a) (the Annual Meeting Rule).
• The 2025 annual meeting of stockholders, initially convened on December 31, 2025, was adjourned due to insufficient votes to constitute a quorum.
• The annual meeting is scheduled to reconvene at 8:00 a.m., Pacific Time, on Friday, January 30, 2026, to allow stockholders more time to vote on proposals, including the ratification of Malone Bailey LLP as the independent auditor for fiscal year 2026.
• Nasdaq's notice states that this non-compliance could serve as an additional basis for a delisting determination.
• This new issue compounds a previously disclosed deficiency of $2.5 million in minimum stockholders' equity under Listing Rule 5550(b)(1) (the Equity Rule), which was disclosed on November 19, 2025.
• The company has incorporated its plan to regain compliance with the Annual Meeting Rule into its existing hearing presentation before a Nasdaq Hearing Panel concerning the Equity Rule deficiency.
• The Nasdaq notice does not immediately impact the trading of the company's common stock, which will continue to be listed on Nasdaq pending the outcome of the hearing process.

Sentiment

Score: 3

Explanation: The filing indicates significant corporate governance and financial compliance issues, with an additional delisting threat from Nasdaq. While the stock is not immediately delisted, the accumulation of non-compliance issues and the lack of assurance regarding regaining compliance present a negative outlook.

Positives

• The Nasdaq notice has no immediate impact on the listing of the company's common stock, which continues to trade.
• Management intends to take all reasonable measures to regain compliance with Nasdaq Listing Rules.

Negatives

• Received a Nasdaq notice of non-compliance with Listing Rule 5620(a) for failing to hold its annual meeting by the required deadline.
• This non-compliance could be an additional basis for delisting, compounding a previously disclosed $2.5 million minimum stockholders' equity deficiency.
• The 2025 annual meeting was adjourned due to insufficient votes to constitute a quorum, indicating potential shareholder disengagement or disagreement.

Risks

• There is no assurance that the company will be able to regain compliance with all applicable continued listing requirements.
• There is no assurance that the company's appeal of the delist determination related to compliance with the Equity Rule (previously disclosed on November 19, 2025) will be successful.
• The non-compliance with the Annual Meeting Rule could lead to an additional basis for a delisting determination by Nasdaq.

Future Outlook

The company intends to take all reasonable measures to regain compliance with Nasdaq Listing Rules and remain listed. However, there is no assurance that it will successfully regain compliance or that its appeal regarding the existing delisting determination for the Equity Rule will be successful.

Management Comments

• "The Company acknowledged the Annual Meeting deficiency and built its plan of compliance for the Annual Meeting Rule into its hearing presentation before a Nasdaq Hearing Panel."
• "The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq."

Industry Context

This situation highlights the critical importance of corporate governance and maintaining minimum financial thresholds for public companies. Non-compliance with listing rules, particularly regarding shareholder meetings and financial health, can severely impact investor confidence and a company's ability to access capital markets, a common challenge for smaller biotech or development-stage companies.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Face increased uncertainty regarding the company's continued listing on Nasdaq, potential for delisting, and the need to vote at the reconvened annual meeting. The inability to achieve a quorum suggests a lack of shareholder participation or consensus.
• Management/Board: Under pressure to resolve multiple Nasdaq compliance issues and ensure the company remains listed, requiring significant effort and potentially impacting strategic focus.
• Employees: Potential impact on morale and stability due to ongoing listing uncertainties.

Next Steps

• The 2025 annual meeting of stockholders will reconvene on January 30, 2026.
• The company will await the decision from the Nasdaq Hearing Panel regarding its plan to regain and maintain compliance for both the Equity Rule and the Annual Meeting Rule.
• The company intends to take all reasonable measures to regain compliance with Nasdaq Listing Rules.

Key Dates

Recommendation

The company faces significant and compounding regulatory challenges, including two distinct Nasdaq non-compliance issues: a $2.5 million stockholders' equity deficiency and a failure to hold its annual meeting due to lack of quorum. The latter has resulted in an additional delisting threat. While the stock is not immediately delisted, the cumulative nature of these issues, coupled with the explicit statement of 'no assurance' regarding regaining compliance or successful appeal, indicates a high probability of delisting or severe stock price depreciation. This situation points to fundamental governance and financial health problems, making the stock a high-risk investment with substantial downside potential.

Keywords

ARTELO BIOSCIENCES, ARTL, Nasdaq, Delisting, Compliance, Annual Meeting, Stockholders' Equity, Corporate Governance, SEC Filing, 8-K